Marc Güell

New gene editing technologies, such as gene drive tools, open the door to deliberately extinguishing species. An analysis article published in Science examines the ethical implications of this possibility based on three specific examples: the eradication of rats, the cattle barren worm, and the Anopheles gambiae mosquito, which transmits malaria. The analysis attempts to answer the question: ‘When and under what circumstances could the intentional eradication of a species be justified?".

A team from the Children's Hospital of Philadelphia and Penn Medicine (United States) has successfully treated a baby diagnosed with a rare genetic disorder using personalised CRISPR gene editing therapy. The baby, known only by the initials KJ, was born with a rare metabolic disease known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. After spending the first months of his life in hospital on a very restrictive diet, KJ received the first dose of his tailored therapy in February 2025, between six and seven months of age. The treatment, which is being used for the first time for this type of disorder, was administered safely, and the baby is now growing well and improving. The case is detailed in a study published by The New England Journal of Medicine (NEJM).

Thirty eight scientists from different specialties, including Craig Venter, a pioneer in the creation of artificial synthetic life, have written an article in the journal Science in which they assess the possibilities of synthesizing mirror organisms, but also warn of the risks they pose. This type of microorganisms, which would present a mirror structure to that currently found in nature, would have potential applications due to their resistance to biological degradation. However, they would also pose a danger because they would not be recognized by our defenses and could spread in ecosystems. Scientists call for more research and a broad debate, and warn that until more is known, this type of organism should not be created. 

The Royal Swedish Academy of Sciences has awarded the Nobel Prize in Chemistry 2024 on the one hand to David Baker for computational protein design, which makes it possible to construct proteins with functions not present in nature. On the other hand, jointly to Demis Hassabis and John M. Jumper of Google DeepMind, for the development of AlphaFold2, which allows the structure of the 200 million known proteins to be predicted at high speed. 

Epigenetic editing is a technique that aims to alter gene expression without the need to modify the DNA sequence, as gene editing techniques do. In this way, Italian researchers have succeeded in silencing the PCSK9 gene in mice, thereby reducing cholesterol levels by half for at least a year. According to the authors, and assuming further evaluation is needed, their platform "could lay the foundations for the development of this type of therapy". The results are published in the journal Nature.

A team of scientists led by the Catholic University of America in Washington has designed new artificial vectors based on viruses to improve gene therapy processes. The main novelty is that they are constructed from viruses that infect bacteria. Among other advantages, this would make it possible to avoid the possible memory of our defences against them and have a greater capacity. According to the authors, who publish their results in the journal Nature Communications, these nanoparticles "have the potential to transform gene therapies and personalised medicine".